KRAS and colorectal carcinoma: Mechanistically, the BR combination, but not single agents, ablates high Myc levels in mutant KRAS CRC, leading to unresolvable proteostress and cell death with a transcrptomic signature charaterized by proteotoxicity, oxidative stress, metabolic suppression, and immune activation (Fig. 6j).